Bioverativ

Bioverativ Inc.

Company type	Public (until 2018)
Industry	Biotechnology, Pharmaceutical
Predecessor	Biogen hemophilia drug segment
Founded	May 2016 (2016-05)
Defunct	March 8, 2018 (2018-03-08)
Fate	Acquired by Sanofi
Headquarters	United States
Area served	United States, European Union, Japan, Canada, Australia
Products	Alprolix, Eloctate, TNT009 (via True North Therapeutics acquisition)
Parent	Sanofi (since 2018)

Bioverativ Inc. is a U.S.-based global biotechnology firm focused on developing treatments for haemophilia. It operates in a competitive landscape alongside companies such as Baxalta (which was acquired by Shire Plc in 2016), Pfizer, and Novo Nordisk. Prior to its purchase by Sanofi on March 8, 2018, Bioverativ was publicly traded on NASDAQ under the symbol BIVV.

History

In May 2016, Biogen declared its intention to create a separate publicly traded company by spinning off its hemophilia drug segment, which included products Eloctate and Alprolix. By August of the same year, the new company was named Bioverativ, maintaining a connection to Biogen’s legacy, with the spin-off scheduled for early 2017. The Securities and Exchange Commission granted approval for Bioverativ’s registration in December, enabling the official separation to occur in February 2017. Biogen shareholders received a special dividend consisting of one Bioverativ share for every two shares of Biogen they owned as of January 17. Trading of Bioverativ stock commenced on January 12, 2017.

In May 2017, Bioverativ announced its acquisition of True North Therapeutics for $825 million, thereby incorporating TNT009—a therapy targeting cold agglutinin disease—into its product portfolio.

Sanofi agreed to acquire Bioverativ in January 2018 for $11.6 billion, enhancing its presence in the hemophilia and rare blood disorder treatment markets.

Acquisition history

Significant mergers and acquisitions undertaken by the company include:

Products

Bioverativ offers two principal products: Alprolix and Eloctate. Together, these therapies generated $604 million in revenue during 2015 and $640 million within the first three quarters of 2016. These figures represented roughly 6% of Biogen’s overall revenue during that period. The products are distributed across multiple regions including the United States, European Union, Japan, Canada, and Australia.